FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281631049> ?p ?o ?g. }

• W4281631049 endingPage "e0269399" @default.
• W4281631049 startingPage "e0269399" @default.
• W4281631049 abstract "The VELOUR study showed the benefit of FOLFIRI-Aflibercept (FA) versus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in second-line treatment. However, only 36% of the included patients were ≥65 years. Thus, we seek to evaluate the efficacy and safety of FA in the elderly population in the context of routine practice.We conducted an observational, retrospective, multicenter, observational study of patients ≥70 years with mCRC treated with FA after progression to oxaliplatin chemotherapy in routine clinical practice in 9 hospitals of the GITuD group.Of 388 patients treated with FA between June 2013 and November 2018, 75 patients ≥70 years were included. The median number of cycles was 10 and the objective response (ORR) and disease control rates (DCR) were 33.8% and 72.0%, respectively. With a median follow-up of 27.1 months, median Progression-free survival (PFS) was 6.6 months and median Overall Survival (OS) was 15.1 months. One third fewer metastasectomies were performed in the ≥75 years' subgroup (24 vs. 52%, p = 0.024) and more initial FOLFIRI dose reductions (68 vs. 36%, p = 0.014). ORR (23.8% vs. 38.3%), DCR (42.8% vs. 85.1%), and PFS (4 vs. 7.8 months; p = 0.017) were significantly less, without difference in OS (9.9 vs. 17.1 months; p = 0.129). The presence of prior hypertension (HT) (PFS 7.9 vs. 5.7 months, p = 0.049) and HT ≥ grade 3 during treatment (PFS 7.6 vs. 6.6 months, p = 0.024) were associated with longer PFS. The most frequent grade 3/4 adverse events were: asthenia (21.3%), neutropenia (14.7%), and diarrhea (14.7%). 57.3% required FOLFIRI dose reduction; 34.7% of aflibercept, including discontinuation (5.3% and 18.7%, respectively).FA combination is effective in patients ≥70 years. The occurrence of HT is predictive of efficacy. Close monitoring of toxicity and initial dose adjustment is recommended." @default.
• W4281631049 created "2022-06-13" @default.
• W4281631049 creator A5000975551 @default.
• W4281631049 creator A5004520470 @default.
• W4281631049 creator A5019273753 @default.
• W4281631049 creator A5030573225 @default.
• W4281631049 creator A5037635576 @default.
• W4281631049 creator A5054832328 @default.
• W4281631049 creator A5060663818 @default.
• W4281631049 creator A5061267781 @default.
• W4281631049 creator A5063796395 @default.
• W4281631049 creator A5065484381 @default.
• W4281631049 creator A5073278280 @default.
• W4281631049 creator A5079835111 @default.
• W4281631049 creator A5080909487 @default.
• W4281631049 date "2022-06-03" @default.
• W4281631049 modified "2023-10-18" @default.
• W4281631049 title "Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen" @default.
• W4281631049 cites W2075457174 @default.
• W4281631049 cites W2115735904 @default.
• W4281631049 cites W2127960841 @default.
• W4281631049 cites W2159034771 @default.
• W4281631049 cites W2404928889 @default.
• W4281631049 cites W2470575266 @default.
• W4281631049 cites W2522918235 @default.
• W4281631049 cites W2605964154 @default.
• W4281631049 cites W2609363527 @default.
• W4281631049 cites W2750068348 @default.
• W4281631049 cites W2789875715 @default.
• W4281631049 cites W2990459257 @default.
• W4281631049 cites W3012415429 @default.
• W4281631049 cites W3128646645 @default.
• W4281631049 cites W4230886463 @default.
• W4281631049 cites W3117633186 @default.
• W4281631049 doi "https://doi.org/10.1371/journal.pone.0269399" @default.
• W4281631049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35657983" @default.
• W4281631049 hasPublicationYear "2022" @default.
• W4281631049 type Work @default.
• W4281631049 citedByCount "2" @default.
• W4281631049 countsByYear W42816310492021 @default.
• W4281631049 crossrefType "journal-article" @default.
• W4281631049 hasAuthorship W4281631049A5000975551 @default.
• W4281631049 hasAuthorship W4281631049A5004520470 @default.
• W4281631049 hasAuthorship W4281631049A5019273753 @default.
• W4281631049 hasAuthorship W4281631049A5030573225 @default.
• W4281631049 hasAuthorship W4281631049A5037635576 @default.
• W4281631049 hasAuthorship W4281631049A5054832328 @default.
• W4281631049 hasAuthorship W4281631049A5060663818 @default.
• W4281631049 hasAuthorship W4281631049A5061267781 @default.
• W4281631049 hasAuthorship W4281631049A5063796395 @default.
• W4281631049 hasAuthorship W4281631049A5065484381 @default.
• W4281631049 hasAuthorship W4281631049A5073278280 @default.
• W4281631049 hasAuthorship W4281631049A5079835111 @default.
• W4281631049 hasAuthorship W4281631049A5080909487 @default.
• W4281631049 hasBestOaLocation W42816310491 @default.
• W4281631049 hasConcept C121608353 @default.
• W4281631049 hasConcept C126322002 @default.
• W4281631049 hasConcept C141071460 @default.
• W4281631049 hasConcept C143998085 @default.
• W4281631049 hasConcept C151730666 @default.
• W4281631049 hasConcept C2776694085 @default.
• W4281631049 hasConcept C2776705615 @default.
• W4281631049 hasConcept C2777802072 @default.
• W4281631049 hasConcept C2778749236 @default.
• W4281631049 hasConcept C2779343474 @default.
• W4281631049 hasConcept C2780259306 @default.
• W4281631049 hasConcept C2780739268 @default.
• W4281631049 hasConcept C2780962732 @default.
• W4281631049 hasConcept C2781413609 @default.
• W4281631049 hasConcept C2908647359 @default.
• W4281631049 hasConcept C526805850 @default.
• W4281631049 hasConcept C71924100 @default.
• W4281631049 hasConcept C86803240 @default.
• W4281631049 hasConcept C90924648 @default.
• W4281631049 hasConcept C99454951 @default.
• W4281631049 hasConceptScore W4281631049C121608353 @default.
• W4281631049 hasConceptScore W4281631049C126322002 @default.
• W4281631049 hasConceptScore W4281631049C141071460 @default.
• W4281631049 hasConceptScore W4281631049C143998085 @default.
• W4281631049 hasConceptScore W4281631049C151730666 @default.
• W4281631049 hasConceptScore W4281631049C2776694085 @default.
• W4281631049 hasConceptScore W4281631049C2776705615 @default.
• W4281631049 hasConceptScore W4281631049C2777802072 @default.
• W4281631049 hasConceptScore W4281631049C2778749236 @default.
• W4281631049 hasConceptScore W4281631049C2779343474 @default.
• W4281631049 hasConceptScore W4281631049C2780259306 @default.
• W4281631049 hasConceptScore W4281631049C2780739268 @default.
• W4281631049 hasConceptScore W4281631049C2780962732 @default.
• W4281631049 hasConceptScore W4281631049C2781413609 @default.
• W4281631049 hasConceptScore W4281631049C2908647359 @default.
• W4281631049 hasConceptScore W4281631049C526805850 @default.
• W4281631049 hasConceptScore W4281631049C71924100 @default.
• W4281631049 hasConceptScore W4281631049C86803240 @default.
• W4281631049 hasConceptScore W4281631049C90924648 @default.
• W4281631049 hasConceptScore W4281631049C99454951 @default.
• W4281631049 hasIssue "6" @default.
• W4281631049 hasLocation W42816310491 @default.
• W4281631049 hasLocation W42816310492 @default.

• next